Bristol Myers Squibb (Israel) Ltd.

Antineoplastic, Engineered Autologous T Cell Immunotherapy product. idecabtagene vicleucel 260 - 500 x 10^6.
For autologous use only. Tmt. consists of a sgle dose for inf. containing a dispersion of CAR-pos. viable T cells in one or more bags. The target dose is 420 x 10⁶ CAR-pos. viable T cells within a range of 260 to 500 x 10⁶ CAR-pos. viable T cells.
For adults with relapsed and refractory multiple myeloma who have received at least two prior ther., incl. an immunomodulatory agent, a proteasome inhib. and an anti-CD38 antibody and have demonstr. dis. progress. on the last ther.
C/I:  Hypersens.

Myosin inhibitor. mavacamten 2.5 mg, 5 mg, 10 mg, 15 mg.
14/28 X  2.5mg, 5mg, 10mg or 15mg
Recommend. starting dose is 5 mg orally once/d without regard to food; allowable subseq. doses with titration are 2.5 mg, 5 mg, 10 mg, or 15 mg orally once/d. The max. recommend. dose is 15 mg /d. See lit.
Tmt. of adults with symptomatic
NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM)
to improve functional capacity and sympt.
C/I:Hypersens. /Moder. to strong CYP2C19 inhibit. or strong CYP3A4 inhibit.
/Moder. to strong CYP2C19 inducers or moder. to strong CYP3A4 inducers.